Compare · GLP-1 agonist
Orforglipron vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Orforglipron | Survodutide | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Orforglipron
Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic…
Survodutide
Survodutide (development code BI 456906) is an investigational injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has a stronger human evidence base than most peptides sold online, including several well-run placebo-controlled trials and one positive Phase 3…